Inteliquet announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Health and Human Services, as represented by the National Cancer Institute (NCI). The principal goal of this research agreement is to develop a clinic-ready, web-based tool, using NCI’s Oncogenomics browser with Inteliquet’s proprietary Precision Medicine Platform to aid clinicians in therapeutic decision-making.